That has left us in both a financially strong position with $184 million of ARR, continuing with a greater than 100% NRR. Long-term relationships with our customers on average, 5 years with some of ...

The drug discount program is under scrutiny on a variety of fronts ...

Another front opens in the battle between hospitals and drugmakers over the 340B drug discount program Good afternoon, and thanks for checking in with the Health Brief newsletter. Please send any tips ...

The 340B program requires pharmaceutical manufacturers to sell drugs at significant discounts — in some cases, extremely ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

Hospitals and contract pharmacies are not required to pass those savings directly to patients at the pharmacy counter. | ...

Advocates for health care providers that treat low-income and uninsured patients are pressuring state lawmakers to pass ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful. The 340B program ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

The legislation pending in the General Assembly is a Senate amendment to House Bill 2371. Sponsored by Sen. Dave Koehler, D-Peoria, it would prohibit anyone, including drug manufacturers, from ...

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.